Last reviewed · How we verify
Insulin Degludec and Insulin Aspart
Insulin Degludec and Insulin Aspart is a Small molecule drug developed by Huashan Hospital. It is currently FDA-approved. Also known as: metformin, linagliptin, Ryzodeg®.
Insulin Degludec and Insulin Aspart, marketed by Huashan Hospital, is a combination therapy for diabetes management with a key composition patent expiring in 2028. The drug's key strength lies in its dual-action mechanism, providing both rapid and long-lasting insulin effects. The primary risk is the upcoming patent expiry, which could lead to increased competition from generic alternatives.
At a glance
| Generic name | Insulin Degludec and Insulin Aspart |
|---|---|
| Also known as | metformin, linagliptin, Ryzodeg® |
| Sponsor | Huashan Hospital |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Regimen Transition After Short-Term Intensive Insulin Therapy in Type 2 Diabetes (PHASE4)
- Evaluate the Efficacy and Safety of GZR101-80 Injection in Patients With Type 2 Diabetes (PHASE2)
- A Research Study Looking at How the Use of NovoPen® 6 for Treatment With Tresiba® & Fiasp® Affects the Blood Sugar Level in Patients With Type 1 Diabetes as Part of Local Clinical Practice
- A Research Study to Compare a New Weekly Insulin, Insulin Icodec, and an Available Daily Insulin, Insulin Degludec, Both in Combination With Mealtime Insulin in People With Type 1 Diabetes (ONWARDS 6) (PHASE3)
- Research Study to Compare a New Medicine "Fast-acting Insulin Aspart" to Another Medicine "Insulin Aspart" in Chinese People With Diabetes (PHASE3)
- Safety and Efficacy of Insulin Degludec/Insulin Aspart in Patients With T2DM (NA)
- iGlarLixi vs IDegAsp in Chinese Participants After OAD(s) (PHASE3)
- Afrezza® INHALE-1 Study in Pediatrics (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Insulin Degludec and Insulin Aspart CI brief — competitive landscape report
- Insulin Degludec and Insulin Aspart updates RSS · CI watch RSS
- Huashan Hospital portfolio CI
Frequently asked questions about Insulin Degludec and Insulin Aspart
What is Insulin Degludec and Insulin Aspart?
Who makes Insulin Degludec and Insulin Aspart?
Is Insulin Degludec and Insulin Aspart also known as anything else?
What development phase is Insulin Degludec and Insulin Aspart in?
Related
- Manufacturer: Huashan Hospital — full pipeline
- Also known as: metformin, linagliptin, Ryzodeg®
- Compare: Insulin Degludec and Insulin Aspart vs similar drugs
- Pricing: Insulin Degludec and Insulin Aspart cost, discount & access